- Case report
- Open Access
Castleman disease mimicked pancreatic carcinoma: report of two cases
© Guo et al.; licensee BioMed Central Ltd. 2012
- Received: 27 April 2012
- Accepted: 6 July 2012
- Published: 23 July 2012
Castleman disease (CD) is an uncommon benign lymphoproliferative disorder, which usually presents as solitary or multiple masses in the mediastinum. Peripancreatic CD was rarely reported. Herein, we report two cases of unicentric peripancreatic CD from our center. A 43-year-old man and a 58-year-old woman were detected to have a pancreatic mass in the routine medical examinations. Both of them were asymptomatic. The computed tomography and ultrasonographic examination revealed a mild enhancing solitary mass at the pancreatic head/neck. No definite preoperative diagnosis was established and Whipple operations were originally planned. The intraoperative frozen section diagnosis of both patients revealed lymphoproliferation. Then the local excisions of mass were performed. Histological examination revealed features of CD of hyaline-vascular type. No recurrence was found during the follow-up period. CD should be included in the differential diagnosis of pancreatic tumors. Local excision is a suitable surgical choice.
- Castleman disease
- Peripancreatic tumor
- Hyaline-vascular type
Castleman disease (CD) is an uncommon benign lymphoproliferative disorder of unknown etiology. It was first described by Castleman in 1956 . There are three pathologic variants: hyaline vascular CD, plasma cell CD, and mixed type of CD is characterized that a patient had features of both hyaline vascular and plasma cell types of CD . Plasmablastic variant of CD, which was considered as a subvariant of plasma cell type, occurs predominantly in immunosuppressed patients and human immunodeficiency virus (HIV)-positive patients . Clinically, CD may present in the forms of unicentric and multicentric. The unicentric variant of CD (UCD) is the most common form of the disease, which is confined to a single lymph-node chain or area, with hyaline vascular type. It is often asymptomatic and curable by surgical excision of the mass. The multicentric variant of CD (MCD) is a less common but more aggressive form. Its corresponding histological pattern is usually the plasma cell and mixed type . Unicentric peripancreatic CD was rarely reported in the published literature. Herein, we report two cases of unicentric peripancreatic CD of hyaline vascular type from our center.
The etiology and pathophysiologic basis of CD remains unclear until now. The chronic inflammation, immunodeficiency state, and autoimmune disorders (such as viral infection involving the human herpes virus 8, the Epstein-Barr virus, or autoimmune hemolytic anemia) are considered to be the possible causal factors of CD. The dysregulation of inflammatory mediators, particularly interleukin-6 (IL-6) secretion has become the leading theory explaining constitutional symptoms and laboratory abnormalities [4, 5]. Of the two patients, case1 was diagnosed as IgA nephropathy which considered an autoimmune disease, and received steroid treatment, but case2 had no inflammatory or autoimmunity disorder. Komatsuda et al.  reported a patient who developed UCD during the course of immunosuppressive therapy for IgA nephropathy associated with cutaneous nodules, the symptoms and abnormal laboratory findings were improved after anti-interleukin-6 receptor antibody administration. Whether case1 with peripancratic CD was associated with IgA nephropathy or immunosuppressive therapy was uncertain.
Clinically, CD is usually divided into unicentric and multicentric types. The UCD is most common with Hyaline vascular type. The mass is usually asymptomatic and localized, and is discovered incidentally, although some patients present with fever, fatigue, and localized pressure symptoms from the mass. The histological findings are of a multiple germinal center surrounded by circumferentially arranged layers in an onionskin pattern, of small lymphocytes, with a prominent vascular stroma and occasional plasma cells, which are characteristic of hyaline-vascular disease.
The preoperative diagnosis of the CD is very difficult. CD most commonly presents as a solitary mass. The classic CT appearance of hyaline vascular CD is that of a solitary enlarged lymph node or localized nodal mass that demonstrate homogeneous intense enhancement after contrast material administration. Diagnostic image sometimes mimics malignancy and CD cannot be identified because of the lack of disease specific signs. Some case reports had introduced an endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) to establish the diagnosis of CD preoperatively [7, 8], however, the sensitivity and specificity of this manner still had not been confirmed by large sample random clinical trial. The diagnosis of CD was still mostly dependent on the postoperative histological examination. Our two patients were both mimicked as carcinoma of pancreas so the preoperative cytologic examinations were not performed.
Surgery, radiotherapy, steroids, immunotherapy (interferon-α or anti-IL-6 antibodies), and combination chemotherapy have all been used to manage the disease . Complete surgical excision remains the most used treatment strategy for unicentric CD, which confers a cure rate approaching 100% . When the lesion is completely removed the prognosis is always perfect. If complete resection is difficult, partial resection may also be helpful, the recurrence rate after subtotal resection is also low . Recurrence of CD after surgical excisions is rarely reported, even if the patients show recurrence, the disease remains progression-free after a repeat resection . Extended surgery, which might cause more morbidity, is not required because CD was considered as a benign procedure. Radiotherapy or chemotherapy may be helpful, but it is not curative and the results vary . Neoadjuvant use of rituximab  and neoadjuvant radiotherapy  have been reported in the treatment of irresectable unicentric CD to reduce tumor size and vascularity to allow for a less morbid surgical resection. In the two patients, during the intraoperative exploration, the occupation was found solitary, and the masses were encapsulated and well demarcated from the attached pancreatic tissue. The intraoperative frozen section diagnosis revealed lymphoproliferation. So the original surgical plans were changed, the Whipple resectiongiven up, and the mildmorbidity local excisions were performed,respectively. When the pathology results were available, chest CT scan and neck ultrasound scan were tested to confirm the tumors were unicentric. The postoperative courses were uneventful. No recurrence was found during the follow-up period. Interestingly, preoperative CA 19–9 of the two patients were slightly elevated, and the CA 19–9 levels were reduced to normal range after the tumor excision. Whether the elevation of serum CA 19–9 level correlated with the CD needs more evidences.
In conclusion, CD should be included in the differential diagnosis of pancreatic tumors. Preoperative and intraoperative differential diagnosis of CD is important. The less morbidity local excision is a suitable surgical choice.
Written informed consent was obtained from the patients for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This work was supported by Projects of Ministry of Public Health(No.2010022015). We thank all the pathologists, particularly Professor ZM Wang, in our hospital for their work on the pathology.
- Castleman B, Iverson L, Menendez VP: Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956, 9: 822-830. 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Cronin DM, Warnke RA: Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009, 16: 236-246. 10.1097/PAP.0b013e3181a9d4d3.View ArticlePubMedGoogle Scholar
- Casper C: The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005, 129: 3-17. 10.1111/j.1365-2141.2004.05311.x.View ArticlePubMedGoogle Scholar
- El-Osta HE, Kurzrock R: Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011, 16: 497-511. 10.1634/theoncologist.2010-0212.PubMed CentralView ArticlePubMedGoogle Scholar
- Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M: The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009, 20: 775-779. 10.1093/annonc/mdn697.View ArticlePubMedGoogle Scholar
- Komatsuda A, Wakui H, Togashi M, Sawada K: IgA nephropathy associated with Castleman disease with cutaneous involvement. Am J Med Sci. 2010, 339: 486-490.PubMedGoogle Scholar
- Yasufuku K, Chiyo M, Sekine Y, Chhajed PN, Shibuya K, Iizasa T, Fujisawa T: Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest. 2004, 126: 122-128. 10.1378/chest.126.1.122.View ArticlePubMedGoogle Scholar
- Khashab MA, Canto MI, Singh VK, Ali SZ, Fishman EK, Edil BH, Giday S: A rare case of peripancreatic Castleman’s disease diagnosed preoperatively by endoscopic ultrasound-guided fine needle aspiration. Endoscopy. 2011, 43 (Suppl 2 UCTN): E128-E130.View ArticlePubMedGoogle Scholar
- Chen CH, Liu HC, Tung KY, Lee JJ, Liu CL, Liu TP: Surgical outcome of superficial and deep Castleman disease. ANZ J Surg. 2007, 77: 339-343. 10.1111/j.1445-2197.2007.04055.x.View ArticlePubMedGoogle Scholar
- Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF: The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer. 1999, 85: 706-717. 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Kim MH, Hwang S, Choi YB, Oh ST, Kim SC, Choi GM, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Yu ES, Lee SG: Castleman disease of the abdomen–single-center experience of 13 surgically treated patients over 11 years. Hepatogastroenterology. 2010, 57: 1060-1063.PubMedGoogle Scholar
- Baek HJ, Kook H, Han DK, Shin MG, Kim HS, Hwang TJ: Unicentric Castleman disease relapsed after fituximab-CHOP chemotherapy or radiation therapy in an adolescent. J Pediatr Hematol Oncol. 2012, 34 (5): e206-e208. PMID:22258344View ArticlePubMedGoogle Scholar
- Bandera B, Ainsworth C, Shikle J, Rupard E, Roach M: Treatment of unicentric Castleman disease with neoadjuvant rituximab. Chest. 2010, 138: 1239-1241. 10.1378/chest.09-2084.View ArticlePubMedGoogle Scholar
- de Vries IA, van Acht MM, Demeyere TB, Lybeert ML, de Zoete JP, Nieuwenhuijzen GA: Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. Radiat Oncol. 2010, 5: 7-10.1186/1748-717X-5-7.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.